Meeting
2023 ASCO Annual Meeting
Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
Authors
George Lau
Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong Special Administrative Region, China
George Lau , Bruno Sangro , Oxana V. Crysler , Wattana Sukeepaisarnjaroen , Oleg Lipatov , Manabu Morimoto , Isabelle Archambeaud , Valentina Burgio , Le Thi Tuyet Phuong , Yee Chao , Jean-Marie Peron , Marie-Luise Berres , Yoo-Joung Ko , Carrie L. McCoy , Charu Gupta , Mallory Makowsky , Alejandra Negro , Ghassan K. Abou-Alfa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03298451
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4073)
DOI
10.1200/JCO.2023.41.16_suppl.4073
Abstract #
4073
Poster Bd #
394
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
First Author: Bruno Sangro
Poster
2018 ASCO Annual Meeting
A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
First Author: Ghassan K. Abou-Alfa
Poster
2017 ASCO Annual Meeting
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
First Author: Robin Kate Kelley
Poster
2023 ASCO Gastrointestinal Cancers Symposium
An open-label, multi-center phase IIIb study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma (TREMENDOUS study).
First Author: Jia Fan